GAMMA Investing LLC Has $168,000 Position in Dr. Reddy’s Laboratories Ltd $RDY

GAMMA Investing LLC increased its position in Dr. Reddy’s Laboratories Ltd (NYSE:RDY) by 102.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,199 shares of the company’s stock after buying an additional 5,676 shares during the quarter. GAMMA Investing LLC’s holdings in Dr. Reddy’s Laboratories were worth $168,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Dr. Reddy’s Laboratories by 2.2% in the first quarter. Vanguard Group Inc. now owns 5,002,642 shares of the company’s stock valued at $65,985,000 after buying an additional 106,457 shares during the period. BNP Paribas Financial Markets increased its position in Dr. Reddy’s Laboratories by 58.0% during the 1st quarter. BNP Paribas Financial Markets now owns 4,583,333 shares of the company’s stock valued at $60,454,000 after purchasing an additional 1,682,363 shares during the period. Millennium Management LLC increased its position in Dr. Reddy’s Laboratories by 53.1% during the 1st quarter. Millennium Management LLC now owns 4,344,000 shares of the company’s stock valued at $57,297,000 after purchasing an additional 1,506,368 shares during the period. Acadian Asset Management LLC increased its position in Dr. Reddy’s Laboratories by 1.6% during the 1st quarter. Acadian Asset Management LLC now owns 1,471,523 shares of the company’s stock valued at $19,404,000 after purchasing an additional 23,582 shares during the period. Finally, American Century Companies Inc. increased its position in Dr. Reddy’s Laboratories by 6.0% during the 1st quarter. American Century Companies Inc. now owns 914,473 shares of the company’s stock valued at $12,062,000 after purchasing an additional 52,108 shares during the period. Institutional investors and hedge funds own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Price Performance

Shares of RDY opened at $13.96 on Tuesday. Dr. Reddy’s Laboratories Ltd has a 12-month low of $12.26 and a 12-month high of $16.19. The business’s fifty day moving average is $14.30 and its 200 day moving average is $14.25. The company has a quick ratio of 1.36, a current ratio of 1.89 and a debt-to-equity ratio of 0.01. The stock has a market cap of $11.65 billion, a P/E ratio of 21.14, a P/E/G ratio of 5.74 and a beta of 0.32.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its earnings results on Wednesday, July 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.02. Dr. Reddy’s Laboratories had a return on equity of 17.25% and a net margin of 16.99%.The company had revenue of $988.82 million for the quarter, compared to analysts’ expectations of $88.27 billion. Sell-side analysts anticipate that Dr. Reddy’s Laboratories Ltd will post 0.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

RDY has been the subject of a number of recent analyst reports. Hsbc Global Res raised shares of Dr. Reddy’s Laboratories from a “hold” rating to a “strong-buy” rating in a research report on Thursday, June 5th. Zacks Research raised shares of Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Finally, HSBC raised shares of Dr. Reddy’s Laboratories from a “hold” rating to a “buy” rating and increased their target price for the company from $14.44 to $16.90 in a research report on Thursday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $16.95.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.